RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists - Trial NCT02112565
Access comprehensive clinical trial information for NCT02112565 through Pure Global AI's free database. This Phase 1 trial is sponsored by City of Hope Medical Center and is currently Active, not recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
City of Hope Medical Center
Timeline & Enrollment
Phase 1
Jun 13, 2016
Dec 31, 2023
Primary Outcome
Maximum tolerated dose of RNR inhibitor COH29, defined as the dose level with no more than 1 dose limiting toxicity (DLT) in the first 6 patients at a dose level below a dose level with DLT in 2 of 6 patients, graded according to CTCAE version 4.0
Summary
This phase I trial studies the side effects and best dose of RNR Inhibitor City of Hope 29
 (COH29) in treating patients with solid tumors that are refractory to standard therapy or for
 which no standard therapy exists. COH29 may inhibit an enzyme called ribonucleotide reductase
 and may interfere with the ability of tumor cells to grow.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02112565
Non-Device Trial